The European Union, consisting of 27 Member States, has continuously worked on improving and streamlining drug review and marketing authorisation processes. There are currently three different procedures that can be used to submit a medicinal product for marketing approval in the EU. This free white paper briefly outlines the available avenues and describes when one might be used over another.